NO20075553L - Substituerte oxazolderivater og deres anvendelse som tyrosinkinaseinhibitorer - Google Patents
Substituerte oxazolderivater og deres anvendelse som tyrosinkinaseinhibitorerInfo
- Publication number
- NO20075553L NO20075553L NO20075553A NO20075553A NO20075553L NO 20075553 L NO20075553 L NO 20075553L NO 20075553 A NO20075553 A NO 20075553A NO 20075553 A NO20075553 A NO 20075553A NO 20075553 L NO20075553 L NO 20075553L
- Authority
- NO
- Norway
- Prior art keywords
- oxazole derivatives
- substituted oxazole
- tyrosine kinase
- kinase inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/46—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Abstract
Den foreliggende oppfinnelse angår nye forbindelser valgt fra substituerte oksazolderivater med formel (I) som selektivt modulerer, regulerer, og/eller inhiberer signaltransduksjon mediert av visse native og/eller mutante tyrosinkinaser implisert i et utvalg av humane og dyresykdommer så som celleprolifererende, metabolske, allergiske og degenerative lidelser. Mer spesielt er disse forbindelsene kraftige og selektive c-kit, bcr-abl- og Fit-3-inhibitorer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66777105P | 2005-04-04 | 2005-04-04 | |
PCT/IB2006/001249 WO2006106437A2 (en) | 2005-04-04 | 2006-04-04 | Substituted oxazole derivatives and their use as tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20075553L true NO20075553L (no) | 2008-01-03 |
Family
ID=36932894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20075553A NO20075553L (no) | 2005-04-04 | 2007-11-02 | Substituerte oxazolderivater og deres anvendelse som tyrosinkinaseinhibitorer |
Country Status (16)
Country | Link |
---|---|
US (2) | US20080242704A1 (no) |
EP (2) | EP1874305B1 (no) |
JP (1) | JP5204643B2 (no) |
KR (1) | KR20080019578A (no) |
CN (1) | CN101217954B (no) |
AU (1) | AU2006231929B2 (no) |
CA (1) | CA2603826C (no) |
HK (1) | HK1112195A1 (no) |
IL (1) | IL186381A (no) |
MX (1) | MX2007012392A (no) |
NO (1) | NO20075553L (no) |
NZ (1) | NZ563097A (no) |
RU (1) | RU2445308C2 (no) |
UA (1) | UA95071C2 (no) |
WO (1) | WO2006106437A2 (no) |
ZA (1) | ZA200709000B (no) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8717411B2 (en) | 2008-02-05 | 2014-05-06 | Olympus Imaging Corp. | Virtual image generating apparatus, virtual image generating method, and recording medium storing virtual image generating program |
AU2012288900B2 (en) * | 2011-07-27 | 2016-10-06 | Ab Science | Selective protein kinase inhibitors |
US20170173056A1 (en) * | 2014-03-20 | 2017-06-22 | Cheryl Lee Eberting | Compositions for the treatment of dermatological diseases and disorders |
US20160175302A1 (en) * | 2014-12-17 | 2016-06-23 | Ab Science | Masitinib for treating gastric cancer |
ES2796276T3 (es) * | 2015-02-05 | 2020-11-26 | Ab Science | Compuestos con actividad antitumoral |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
MY196990A (en) | 2016-07-13 | 2023-05-17 | Leo Pharma As | Heteroaromatic modulators of the retinoid-related orphan receptor gamma |
WO2018106643A1 (en) * | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
TWI667236B (zh) * | 2017-06-13 | 2019-08-01 | 財團法人國家衛生研究院 | 作為蛋白激酶抑制劑的胺基噻唑化合物 |
CN109320473B (zh) * | 2018-10-17 | 2022-11-22 | 南华大学 | 噻唑氨基苯甲酰胺乙酸衍生物及其用途 |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP4025570A4 (en) * | 2019-09-06 | 2022-11-02 | ONO Pharmaceutical Co., Ltd. | HYDANTOINDIVATIVES |
KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3740420A (en) * | 1967-11-28 | 1973-06-19 | Crown Zellerbach Corp | Pharmaceutical compositions with dimethyl sulfoxide |
FR2077803B1 (no) | 1970-02-16 | 1973-03-16 | Innothera Lab Sa | |
US3743727A (en) * | 1970-11-16 | 1973-07-03 | Crown Zellerbach Corp | Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide |
US3989816A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
US4405616A (en) * | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
US4343940A (en) | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
CA1163561A (en) * | 1979-11-06 | 1984-03-13 | Cyril Boroda | Preparation containing nitroglycerine and optionally other medicaments and preparation thereof |
US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4460372A (en) * | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
US4411893A (en) * | 1981-08-14 | 1983-10-25 | Minnesota Mining And Manufacturing Company | Topical medicament preparations |
CA1236029A (en) * | 1984-05-14 | 1988-05-03 | Edmund Sandborn | Pharmaceutical solutions comprising dimethyl sulfoxide |
US4615699A (en) * | 1985-05-03 | 1986-10-07 | Alza Corporation | Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes |
US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
DE3815221C2 (de) * | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
EP0526488B1 (en) | 1990-04-02 | 1994-11-30 | Pfizer Inc. | Benzylphosphonic acid tyrosine kinase inhibitors |
US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
CA2108889A1 (en) | 1991-05-29 | 1992-11-30 | Robert Lee Dow | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
CZ283965B6 (cs) | 1992-08-06 | 1998-07-15 | Warner-Lambert Company | 2-thioindolové, 2-indolinthionové a polysulfidové sloučeniny, 2-selenoindolové, 2-indolinselenonové a selenidové sloučeniny a farmaceutické prostředky na jejich bázi |
US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
JPH06279374A (ja) * | 1993-03-25 | 1994-10-04 | Kanegafuchi Chem Ind Co Ltd | 新規な第1級アミンとその製造方法 |
US5656643A (en) * | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5906202A (en) * | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
PL334304A1 (en) * | 1996-12-24 | 2000-02-14 | Chugai Pharmaceutical Co Ltd | Derivatives of aromatic amines acting as nos inhibitors |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
JP2002528499A (ja) * | 1998-10-29 | 2002-09-03 | ブリストル−マイヤーズ スクイブ カンパニー | Impdh酵素のインヒビターであるアミノ核誘導化合物 |
US6596747B2 (en) * | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
EP1139754A4 (en) | 1998-12-31 | 2002-12-18 | Sugen Inc | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATION OF PROTEIN KINASE ACTIVITY AND IN CANCER CHEMOTHERAPY |
US7678805B2 (en) | 2001-06-29 | 2010-03-16 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD) |
US7700610B2 (en) | 2001-06-29 | 2010-04-20 | Ab Science | Use of tyrosine kinase inhibitors for treating allergic diseases |
US20030091974A1 (en) | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
US20040266771A1 (en) | 2001-06-29 | 2004-12-30 | Alain Moussy | Use of tyrosine kinase inhibitors for treating bone loss |
ATE330608T1 (de) | 2001-06-29 | 2006-07-15 | Ab Science | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen |
US20050054617A1 (en) | 2001-06-29 | 2005-03-10 | Alain Moussy | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
EP1401412A2 (en) | 2001-06-29 | 2004-03-31 | AB Science | Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
JP2005500041A (ja) | 2001-06-29 | 2005-01-06 | アブ サイエンス | 強力で選択的かつ非毒性のc−kit阻害剤 |
US20050176687A1 (en) | 2001-06-29 | 2005-08-11 | Alain Moussy | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
EP1401414A2 (en) | 2001-06-29 | 2004-03-31 | AB Science | Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
CA2461181A1 (en) | 2001-09-20 | 2003-05-01 | Ab Science | Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
US20040242612A1 (en) | 2001-09-20 | 2004-12-02 | Alain Moussy | Use of tyrosine kinase inhibitors for promoting hair growth |
WO2003039550A1 (en) | 2001-09-20 | 2003-05-15 | Ab Science | Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases |
CA2474322A1 (en) * | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
EP1532103A4 (en) * | 2002-06-19 | 2008-03-05 | Bristol Myers Squibb Co | USE OF COMPOUNDS WITH AN AMINKER IN THE MANUFACTURE OF A MEDICAMENT SUITABLE FOR THE TREATMENT OF FACTOR VIIA ASSOCIATED SUFFERERS |
TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
US7189712B2 (en) * | 2002-10-10 | 2007-03-13 | Smithkline Beecham Corporation | 1,3-Oxazole compounds for the treatment of cancer |
WO2004076693A1 (en) * | 2003-02-27 | 2004-09-10 | Ab Science | Tailored treatment suitable for different forms of mastocytosis |
PL1635824T3 (pl) * | 2003-06-03 | 2010-01-29 | Novartis Ag | 5-Członowe heterocykliczne inhibitory P-38 |
US20090048301A1 (en) * | 2003-07-09 | 2009-02-19 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
PL1684750T3 (pl) * | 2003-10-23 | 2010-10-29 | Ab Science | 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej |
GB0326601D0 (en) * | 2003-11-14 | 2003-12-17 | Novartis Ag | Organic compounds |
KR101042490B1 (ko) * | 2004-07-15 | 2011-06-16 | 니뽄 다바코 산교 가부시키가이샤 | 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(vr1)활성 저해제 |
-
2006
- 2006-04-04 CA CA2603826A patent/CA2603826C/en not_active Expired - Fee Related
- 2006-04-04 UA UAA200712205A patent/UA95071C2/ru unknown
- 2006-04-04 NZ NZ563097A patent/NZ563097A/xx not_active IP Right Cessation
- 2006-04-04 EP EP06755876.7A patent/EP1874305B1/en not_active Not-in-force
- 2006-04-04 AU AU2006231929A patent/AU2006231929B2/en not_active Ceased
- 2006-04-04 RU RU2007140864/04A patent/RU2445308C2/ru not_active IP Right Cessation
- 2006-04-04 JP JP2008504871A patent/JP5204643B2/ja not_active Expired - Fee Related
- 2006-04-04 EP EP11160069A patent/EP2361624A1/en not_active Withdrawn
- 2006-04-04 KR KR1020077025402A patent/KR20080019578A/ko active Search and Examination
- 2006-04-04 US US11/910,497 patent/US20080242704A1/en not_active Abandoned
- 2006-04-04 MX MX2007012392A patent/MX2007012392A/es active IP Right Grant
- 2006-04-04 WO PCT/IB2006/001249 patent/WO2006106437A2/en active Application Filing
- 2006-04-04 CN CN2006800196294A patent/CN101217954B/zh not_active Expired - Fee Related
-
2007
- 2007-10-07 IL IL186381A patent/IL186381A/en not_active IP Right Cessation
- 2007-10-19 ZA ZA200709000A patent/ZA200709000B/xx unknown
- 2007-11-02 NO NO20075553A patent/NO20075553L/no not_active Application Discontinuation
-
2008
- 2008-07-08 HK HK08107469.9A patent/HK1112195A1/xx not_active IP Right Cessation
-
2012
- 2012-01-05 US US13/343,968 patent/US8658659B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101217954B (zh) | 2013-07-10 |
JP2008534673A (ja) | 2008-08-28 |
WO2006106437A2 (en) | 2006-10-12 |
US8658659B2 (en) | 2014-02-25 |
EP2361624A1 (en) | 2011-08-31 |
US20080242704A1 (en) | 2008-10-02 |
ZA200709000B (en) | 2008-11-26 |
KR20080019578A (ko) | 2008-03-04 |
US20120108616A1 (en) | 2012-05-03 |
WO2006106437A3 (en) | 2006-11-23 |
RU2445308C2 (ru) | 2012-03-20 |
JP5204643B2 (ja) | 2013-06-05 |
IL186381A (en) | 2014-02-27 |
AU2006231929A1 (en) | 2006-10-12 |
HK1112195A1 (en) | 2008-08-29 |
EP1874305A2 (en) | 2008-01-09 |
WO2006106437A8 (en) | 2007-03-15 |
CA2603826A1 (en) | 2006-10-12 |
IL186381A0 (en) | 2008-01-20 |
NZ563097A (en) | 2011-11-25 |
AU2006231929B2 (en) | 2012-09-06 |
RU2007140864A (ru) | 2009-05-20 |
EP1874305B1 (en) | 2014-08-27 |
MX2007012392A (es) | 2007-12-05 |
CN101217954A (zh) | 2008-07-09 |
UA95071C2 (ru) | 2011-07-11 |
CA2603826C (en) | 2013-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20075553L (no) | Substituerte oxazolderivater og deres anvendelse som tyrosinkinaseinhibitorer | |
NO20075627L (no) | Inhibitorer av cytosolisk fosfolipase A2 | |
MXPA05001277A (es) | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. | |
NO20062308L (no) | 2-aminoarykloksazolforbindelser som tyrosinkinasehemmere | |
BRPI0507271A (pt) | 2-(3-substituìda-aril)amino-4-aril-tiazóis como inibidores de tirosina cinase | |
CY1110663T1 (el) | 2-αμινοαρυλοξαζολικες ενωσεις ως παρεμποδιστες κινασων της τυροσινης | |
NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
NO20081893L (no) | 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft | |
EA201290600A1 (ru) | Тиазольные и оксазольные ингибиторы киназы | |
NO20091326L (no) | Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase | |
NO20076460L (no) | Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav | |
WO2006064375A2 (en) | Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases | |
NO20074634L (no) | Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer | |
NO20075992L (no) | Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav | |
NO20073859L (no) | Pyrrolopyrazoler, potente kinaseinhibitorer | |
NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
TN2009000128A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
NO20064599L (no) | Substituerte morfolin- og tiomorfolinderivater | |
NO20081001L (no) | Derivater av karboksamid som antagonister for muskarinisk reseptor | |
NO20073287L (no) | 2,5 og 2,6-disubstituerte benzazol-analoger som proteinkinaseinhibitorer | |
DK1853232T3 (da) | Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse | |
NO20083045L (no) | Benzimidazolderivater og deres anvendelse til modulering av GABAA-reseptorkomplekset | |
CU23680B7 (es) | Derivados de oxazol sustituidos y su uso como inhibidores de tirosina quinasa | |
NZ618953A (en) | Selective protein kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |